Back to Search Start Over

Use of Primary Macrophages for Searching Novel Immunocorrectors.

Authors :
Nikiforov NG
Elizova NV
Bukrinsky M
Dubrovsky L
Makeev VJ
Wakabayashi Y
Liu P
Foxx KK
Kruth HS
Jin X
Zakiev ER
Orekhov AN
Source :
Current pharmaceutical design [Curr Pharm Des] 2017; Vol. 23 (6), pp. 915-920.
Publication Year :
2017

Abstract

In this mini-review, the role of macrophage phenotypes in atherogenesis is considered. Recent studies on distribution of M1 and M2 macrophages in different types of atherosclerotic lesions indicate that macrophages exhibit a high degree of plasticity of phenotype in response to various conditions in microenvironment. The effect of the accumulation of cholesterol, a key event in atherogenesis, on the macrophage phenotype is also discussed. The article presents the results of transcriptome analysis of cholesterol-loaded macrophages revealing genes involved in immune response whose expression rate has changed the most. It turned out that the interaction of macrophages with modified LDL leads to higher expression levels of pro-inflammatory marker TNF-α and antiinflammatory marker CCL18. Phenotypic profile of macrophage activation could be a good target for testing of novel anti-atherogenic immunocorrectors. A number of anti-atherogenic drugs were tested as potential immunocorrectors using primary macrophage-based model.<br /> (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.)

Details

Language :
English
ISSN :
1873-4286
Volume :
23
Issue :
6
Database :
MEDLINE
Journal :
Current pharmaceutical design
Publication Type :
Academic Journal
Accession number :
28124601
Full Text :
https://doi.org/10.2174/1381612823666170125110128